INTRODUCTION AND AIMS:
Hyperuricemia, defined as a serum uric acid concentration > 7 mg/dl, is a highly common condition among general population, with a prevalence around 13% regardless of sex. Experimental and clinical studies suggest that elevated serum acid uric may influence metabolic and cardiovascular disease. The objective of the present study was to investigate the relationship between serum urate levels and inflammation through the analysis of serum and mRNA expression levels of proinflammatory cytokines. METHODS: Serum concentrations and mRNA expression levels in peripheral blood mononuclear cells (PBMCs) of tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6) were measured in 99 individuals in a cross sectional analysis. In addition, the evolution of these parameters was evaluated in 32 subjects after allopurinol treatment. Serum inflammatory cytokines were measured by a solid phase, chemiluminescent inmunometric method. PBMCs were isolated by density gradient centrifugation and mRNA expression levels were analyzed by real-time quantitative RT-PCR. RESULTS: All participants (56% males, mean age 6067.5 years, 29% diabetics) had an eGFR above 60 ml/min per 1.73m 2 . The mean uric acid level was 6.2 6 1.5 mg/dL. Serum urate concentration were correlated with C-reactive protein (CRP) (R¼0.26, p¼0.009,), IL-6 (R¼0.69, p<0.001) and TNF-a (R¼0.58, p<0.001), as well as with mRNA levels of IL-6 (R¼0.73, p<0.001) and TNF-a (R¼0.54, p<0.001). Participants were stratified according quartiles of serum uric acid levels. Across increasing uric acid, individuals had higher UEA (p for trend <0.001), serum inflammatory markers (CRP, p for trend ¼ 0.003; IL-6 and TNF-a , p for trend < 0.001) and mRNA expression levels in PBMC (IL-6 and TNF-a , p for trend <0.001). Serum acid uric concentration was an independent predictor of serum and mRNA expression levels of inflammatory cytokines in multiple regression models (p<0.01). Treatment with allopurinol in 32 participants was associated with a reduction of serum uric acid concentration, as well as a decrease in the serum and PBMCs expression levels of inflammatory cytokines (p<0.001). There was a significant correlation between the change in serum uric acid with the variation in serum TNF-a (p¼0.01), and the changes in serum and mRNA IL-6 levels (p<0.001). After controlling for the effect of other variables, the direct association between the changes in serum uric acid and the variation in the serum and expression levels of IL-6 remained significant and independent (p<0.01). CONCLUSIONS: In conclusion, there was a direct and independent association between serum uric acid concentration and the serum and mRNA expression levels of pro-inflammatory cytokines. Allopurinol administration reduced serum uric acid, which was associated with modulation of the inflammatory profile. These results provide potential link between hyperuricemia, inflammation and cardiovascular disease. Lowering uric acid with allopurinol improves eGFR, BP and might decrease cardiovascular events in CKD patients. The aim of the study was to investigate the influence of febuxostat on eGFR and BP in non-diabetic patients with CKD 2-3 with mild hypertension and no history of gout in 6 years follow-up. METHODS: Since 2011 56 patients with asymptomatic hyperuricemia and CKD 2-3 (GFR 5463 ml/min) has been enrolling in randomized prospective open-label study in parallel groups: 20 on allopurinol 300 mg, 16 on febuxostat 80 mg and 20 free of treatment as control group. eGFR-EPI, ambulatory BP monitoring, urine albumin-creatinine ratio, and C-reactive protein, fasting blood glucose has been measuring at baseline, and every 6 months. A multiple regression model incorporating variables expected to influence GFR (gender, age, CRP level and systolic/diastolic BP), as well as serum uric acid was performed for people were remaining on this therapy. 38 from them are being analyzed at 6 years follow-up. RESULTS: Age, gender, GFR, level of microalbuminuria and ACE-I/ARB regime were similar in all groups at baseline. Allopurinol treatment as well as febuxostat resulted in a decrease in serum uric acid, a decrease in systolic BP, and an increase in GFR compared with baseline. Febuxostat treatment led to the most beneficial decrease in the level of uric acid (-220617 mmol/l, P0,01 with control and P0,05 with allopurinol group), increased GFR (þ1162 ml/min, P0,01 with control and P0,05 with allopurinol group), blood pressure decrease (-762/-361 mm hg, P0,05 with control and P¼0,92 with allopurinol group), albuminuria (-126620 mg, P0,01 with control and P0,05 with allopurinol group. Potential benefits of febuxostat were better tolerability compared with allopurinol group with target levels of uricemia less 180 mmol/l in 32% of people. CONCLUSIONS: At least 6-year treatment with febuxostat (better than allopurinol) improves GFR and BP in patients with asymptomatic hyperuricemia in non-diabetic CKD 2-3. More studies with febuxostat are necessary to assess the risk/benefit of lowering uric acid in non-diabetic adults with CKD and asymptomatic hyperuricaemia in target group less 180 mmol/l. Dept. Cardiothoracic Sciences, Univ. Campania "L.Vanvitelli", Naples, Italy and INTRODUCTION AND AIMS: Previous data from our and other laboratories have demonstrated that higher urinary volume and glomerular filtration rate (GFR) are inversely correlated. We have previously shown that patients with central diabetes insipidus have low GFR, which can be increased by ddAVP (Minirin). We have published very preliminary studies on the renal hemodynamic response to a protein meal indicating that GFR response might be absent or delayed in diabetes insipidus (DI). The aim of this study is to analyze the hemodynamic response to a meat meal in DI patients before and after treatment with ddAVP and comparison have been also made with normal subjects. METHODS: To this aim, thirteen adult patients with central DI and age-and body weight-matched controls participated in this study. Subjects have been parametrized at basal level and the GFR measured by inulin method at baseline and at various times after a proteic meal. RESULTS: At baseline patients with DI had lower systolic blood pressure (SBP), lower creatinine clearance, lower GFR (inulin method), lower Urine osmolarity, higher Urine Na per day and higher urinary volume (6.6ml/min in DI vs 0.89ml/min in controls). Following a meat meal in normal subjects, there was a post-meal GFR increase with a peak at 60min that returned to baseline within 130min. In patients with DI, there was only a late post-meal GFR increase (130-180 min).Patients with DI were studied again after three weeks treatment with ddAVP (Minirin), which caused a significant reduction of their urinary flow rate (1.85ml/min). Treated patients underwent a second meat-meal, which caused an anticipation of the post-meal GFR peak (60-130min). Treatment with ddAVP resulted in an increase in SBP, creatinine clearance, GFR, urine osmolarity, a reduction in urinary Na and K excretion and plasma osmolarity. CONCLUSIONS: The data confirm that lack of ADH causes a significant reduction in GFR. They indicate that lack of ADH causes a delayed post-meal GFR response, which is partly corrected by administration of ddAVP.The results show that likely the early phase of protein-dependent hyperfiltration is dependent on ADH, whereas the late phase is ADH independent. The results add new interpretation of the renal reserve in pathological conditions. 
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INTRODUCTION AND AIMS:
Patients with primary hyperoxaluria type 1 have an elevated endogenous oxalate production leading to intrarenal calcium oxalate crystal deposition (nephrocalcinosis) and CKD progressing to end-stage renal disease. The acute phase protein Pentraxin 3 (PTX3) exerts a variety of regulatory functions in acute and chronic tissue inflammation. In particular, PTX3 acts as an opsonin for a variety of pathogens and endogenous particles. We hypothesized, that PTX3 would exhibit opsonin-like functions also on calcium oxalate crystals and inhibiting crystal growth and nephrocalcinosis. METHODS: Direct effects of PTX3 on calcium oxalate crystals were investigated in chemico using standard imaging techniques. To study the role of PTX3 in vivo, we used a murine model of hyperoxaluria induced nephrocalcinosis where Ptx3-deficient B6;129-mice or their PTX3-competent littermates were fed with a high-oxalate diet for 21 days. PTX3 protein levels were assessed by Western blot and immunohistochemistry. Assessment of nephrocalcinosis and CKD progression was conducted by histochemistry, flow cytometry and fluorescein isothiocyanate-labeled sinistrin clearance using non-invasive, transcutaneous imagers.
RESULTS: Adding PTX3 to supersaturated calcium and oxalate in-chemico dosedependently inhibited crystal growth, while an isomolar albumin control did not (A). PTX3 protein was undetectable in the urine of wildtype mice under physiological conditions but increased within 3 weeks of feeding an oxalate-rich diet to induce nephrocalcinosis. Most likely the urinary PTX3 originated directly from tubular epithelial cells, as immunhistochemistry of kidney sections indicated a high induction of protein expression in these cells. To test for a functional role of PTX3 we designed an in vivo experiment where Ptx3-deficient B6;129-mice as well as their wildtype littermates were exposed to oxalate-rich diet for 3 weeks, although mice of this specific genetic background are not susceptible to hyperoxaluria-induced nephrocalcinosis. However, lack of PTX3 induced profound nephrocalcinosis in B6;129 mice associated with interstitial inflammation and fibrosis as well as a linear decline in glomerular filtration rate (B-D). Nephrocalcinosis and CKD were absent in their Ptx3þ/þ littermates (B-D).
CONCLUSIONS: Thus, PTX3 is an endogenous inhibitor of calcium oxalate crystallization even in profound hyperoxaluria. It will be interesting to look into the precise mechanism of action and to develop therapeutic strategies to exploit this novel found function of PTX3 to prevent nephrocalcinosis in primary hyperoxaluria, a disease with currently very few treatment options.
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